Imaging Center COE Articles

Articles

  • (44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617-preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617.

    The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes of prostate cancer. Radiolabeled PSMA-617, a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-functionalized PSMA ligand, revealed favorable kinetics with high tumor uptake, enabling its successful application for PET imaging ((68)Ga) and radionuclide therapy ((177)Lu) in the clinics.

    Published January 26, 2017
  • (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

    The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of (68)Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of (68)Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.

    Published March 13, 2017
  • 68 Ga-PSMA Uptake by Dermatofibroma in a Patient With Prostate Cancer.

    Prostate-specific membrane antigen (PSMA) is a typ. 2 transmembrane protein that is highly expressed in prostate cancer cells. Ga-PSMA PET/CT imaging is a modality used to determine the extent of prostate cancer.

    Published March 8, 2017
  • A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III)

    The advanced prostate cancer therapeutic landscape has changed dramatically over the last several years, resulting in improved overall survival for patients with both castration-naive and castration-resistant disease. The evolution and development of novel next-generation imaging (NGI) techniques will affect diagnostic and therapeutic decision-making. Clinicians must navigate when and which NGI techniques to use and how to adjust treatment strategies based upon their results, oftentimes in the absence of correlative therapeutic data. Therefore, guidance is needed based on the best available information and current clinical experience.
    Published August 7, 2018
  • A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT: Beyond the Abstract

    Nearly 20 years ago, a new radiation therapy planning system was approved for clinical use ushering in the era of intensity modulated radiotherapy (IMRT). IMRT divides a large uniform field of radiation into many tiny beamlets, each of varying intensity or strength. This breakthrough allowed one to better conform the dose of radiotherapy to an irregular target and spare the adjacent normal tissues. Its use in prostate radiotherapy spread rapidly and today, IMRT is the most frequently used radiation modality for prostate cancer. In Arizona, at Mayo Clinic, we see a large number of men with prostate cancer.
    Published April 5, 2017
  • ASCO GU 2019: Randomized Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

    San Francisco, CA (UroToday.com)  Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients with PSA < 1 ng/mL, a threshold at which standard-of-care imaging is not sensitive enough to detect disease recurrence.  68Ga-PSMA-11 PET/CT (PSMA) PET/CT molecular imaging is highly sensitive for detecting regional and distant metastatic recurrent prostate cancer at low PSA levels. This lead to the assumption that PSMA can help guide and improve SRT.  
    Published February 15, 2019
  • ASCO GU 2019: Results of a 50 Patient Single-Centre Phase II Prospective Trial of Lutetium-177 PSMA-617 Theranostics in mCRPC

    San Francisco, CA (UroToday.com) PSMA is over-expressed in all prostate tissue, including prostatic carcinoma. Lutetium-177 (177Lu)-PSMA617 (LuPSMA) is a small radiolabeled molecule which binds to PSMA and delivers a dose of β radiation. Lutetium-177 is a good partner to help deliver the radiation because of the short range β radiation (maximal tissue penetration of <2mm), thereby decreasing the potential collateral damage to nearby organs. 
    Published February 16, 2019
  • Assessment of Simplified Methods for Quantification of 18F FDHT Uptake Scans in Patients with Metastasized Castrate-Resistant Prostate Cancer - Gem Kramer

    (Length of Presentation: 8 min)

    This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer.

    Biographies:

    Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands


    Read the Full Video Transcript

    Gem Kramer: Thank you very much for the introduction. First, this study was financially supported by the Movember Foundation. 

    So as we all know, the androgen receptor is critical for the development of prostate cancer and is one of the motors in early stage prostate cancer. However, even if the prostate cancer had progressed into castration-resistant prostate cancer, it remains to play a role in either through ligand-dependent activation, like overexpression or de novo androgenesis the tumor itself or through ligand-independent activation.

    So, recently, in recent years, all kinds of new therapies have been developed like enzalutamide or abiraterone targeting these androgen receptors, however, 50% of the patients receiving these treatments remain non-responders. And to avoid unnecessary treatment and costs it will be very nice to have a prognostic imaging biomarker, in this case, imaging, to evaluate response and to indicate which patients are going to respond to therapy and which not. 

    This is where the FDHT comes in. The F18 fluorodihydrotestosterone, so actually it's fluorine labeled to dihydrotestosterone, as we see on the picture to the right and this enables you to noninvasively image androgen receptors. So if you want to use this tracer as a biomarker you can do it using visualization, but if you want to adequately assess response one would need quantification as well.

    The golden standard, of course, is a non-linear regression. Only this is not generally applicable in clinical practice, so, therefore, we need more simplified methods.  The aim of this study was, therefore, to assess whether the simplified methods for quantification of FDHT uptake in patients with mCRPC are adequate. 

    So, what did we do in this study? First, we tried to determine which was the optimal non-linear model describing the pharmacokinetics of FDHT. Second, we looked at continuous arterial sampling versus image-derived input function, and calibrate for arterial and venous samples and see where it was possible to leave the continuous arterial sampling out. Second, we looked at linearization models like Patlak and Logan plots and compared them to non-linear regression. And last, but not least, we looked also at different static methods of simplification. So, the most simple of body weight but also tissue to blood ratio and sort of corrected for the parent plasma. As you see here, this line is the FDHT so the parent plasma of FDHT. And you see it rapidly metabolizes, so after 30 minutes there's almost nothing left. So we also correct for this rapid metabolization and through correcting for parent plasma and also for the area on the curve plasma. 

    We included eight patients for this study, both test and retest data. Four scans were available with continuous arterial sampling, arterial samples, and venous sampling. And 12 were available using only venous samples. And only patients with mCRPC were included, so they do have testosterone levels lower than 1.7 nanomoles per liter. And they had to have progressive disease according to PSA rise or new lesions according to imaging through RECIST or two new lesions on a bone scan. And they were excluded if they were already treated with anti-androgens, like enzalutamide, or at a low HB so you couldn't do the arterial sampling.

    So the scan protocol was as follows. First, there was a dynamic FDHT-PET scan for 30 minutes using continuous arterial sampling. And also we did five arterial manual samples to correct for metabolites later on, and three venous to compare those. After this first dynamic scan, we took a short break of 15 minutes, where the patient had to go to the toilet and when he came back we put him on the table again and we did a whole body FDHT-PET scan at 45 minutes post-injection. 

    Using the scans, we obtained than an image-derived input function by placing a writ of interest in the ascending aorta and calibrating those with the venous and arterial samples. And we did the same, we also obtained a writ of interest for the tumor TAC by using a 50 percent --. 

    Using this data, we performed a nonlinear aggression to obtain the optimal model like I already explained and we found that the two tissue 3K model with bloodborne infection was a model ultimately describing the pharmacokinetics. This is an irreversible model, we are going to be looking at Ki for now.

    We compared the Ki of the continuous sampling with the Kiof the image derived input function with corrected for venous sampling and we saw a near perfect correlation of 0.89 of 98th. So wherefore assumed that we can replace the arterial sampling by need of at least corrected for three venous samples. 

    We looked further. We went to the Patlak and Logan analysis and compared those and what we found was that the Patlak always gave normal varies where Logan had a lot of misfits, which we suspected cause Logan actually is more likely to, irreversible traces where this was more irreversible. And here if you compare the Ki on nonlinear aggression with the Patlak Ki, also see a good correlation. 

    The only thing of this method, the nonlinear regression is you need the extra scan, for cleaning would be nice to use the extra scan so we looked at SUV body weight and what we saw here was that the correlation went down to the S squared was only 0.77 but there seems to be kind of split in the data so we were looking further into this. And this data is actually of one patient while the other 12 patients are on the other line shown a really good correlation of still above 0.90. So looked into this individual patient previous, really early in the disease and also fast progressive so this might be a different kind of metabolism is not, faster metabolizer compared to the patient who is already further in their disease. This was one with no treatment, no dose, no nothing before this.

    So we tried to correct for this and actually was using the tissue to blood ratio and we found that actually here the surf corrected for the area of the curve of current plasma completely reversed the effect, no outline anymore. Suggesting also this is the metabolism of the tracer is different in this one patient and if you look for the other ways to simplify it you see that it doesn't really change. So if you correct serve only for the parent plasma or blood concentration the R squared stays more or less the same.

    In conclusion, quantification of FDHG update performed using the simplified method, it's possible. We can replace the continuous arterial sampling by -- if you use the surf correctly the area of the curve of parent plasma or the Patlak you get a near perfect correlation. However, you need an extra scan also to obtain the area on the curve of parent plasma and when you further simple case the methods this results in a decreased accuracy of the scans and the quantification. These are the acknowledgments, I would like to thank you for your attention.
    Published October 17, 2017
  • Axumin™ [Fluciclovine F18]: An Accurate Imaging Approach for Patients with Biochemically Recurrent Prostate Cancer

    Published in Everyday Urology - Oncology Insights: Volume 1, Issue 2
    Prostate cancer [PCa] affects 1 man in 7 in the United States, making this the most commonly diagnosed non-cutaneous cancer in males.  Although an ever-increasing number of treatment options exist, an estimated 26,100 men will still die of the disease in the US in 2016, generally after primary local and systemic treatments for prostate cancer have failed.
    Published November 17, 2016
  • Clinical translation of a PSMA inhibitor for (99m)Tc-based SPECT.

    Prostate-specific membrane antigen (PSMA) is highly over-expressed in advanced prostate cancers. (68)Ga-labeled PSMA inhibitors (iPSMA) are currently used for prostate cancer detection by PET imaging.

    Published February 24, 2017
  • Co-Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody-Conjugated BSA-PEI Layer-by-Layer Nanoparticles for Prostate Cancer Target Therapy.

    How to overcome the low accumulation of chemotherapeutic agent in tumor tissue and exhibit multitherapeutics remains an ongoing challenge for cancer treatment. Here, a simple method is demonstrated that used to prepare prostate-specific membrane antigen antibody (PSMAab )-conjugated fluorescent bovine serum albumin (BSA)-branched polyethylenimine layer-by-layer nanoparticles (BSA-PEILBL NPs) for co-delivery of docetaxel (DTX) and p44/42 mitogen-activated protein kinase (MAPK) small interfering RNA (p44/42 MAPK siRNA) as synergistic and selective inhibition of cancer cell proliferation platform.

    Published February 3, 2017
  • Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.

    The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [(68)Ga]PSMA I&T.

    Published March 15, 2017
  • EAU 2019: The Imaging Specialist’s Perspective on MRI for Prostate Cancer

    Barcelona, Spain (UroToday.com) Dr. Rouviere presented the imaging specialist’s perspective on MRI use in prostate cancer. According to the European Association of Urology (EAU) guidelines prostate multiparametric MRI (mpMRI) was originally recommended after a negative prostate biopsy before a repeat biopsy (2015). Later, mpMRI was recommended before a confirmatory biopsy in candidates for active surveillance (2016), and recently it has been recommended before a first set of biopsy, in biopsy naïve men (2019).
    Published March 15, 2019
  • EAU 2019: Theranostics: The Future of Functional Imaging

    Barcelona, Spain (UroToday.com) Theranostics is an emerging field of medicine which utilizes targeted cancer therapy based on specific molecular-targeted diagnostic tests. As part of the Imaging in Prostate Cancer plenary session at the 2019 European Association of Urology (EAU) annual meeting in Barcelona, Spain, Dr. Stefano Fanti, Director of Nuclear Medicine and Professor of diagnostic imaging at the the University of Bologna, discussed the potential uses of theranostics as it relates to the future of prostate cancer treatment.
    Published March 19, 2019
  • ESOU 2019: Radiotherapy: High Quality Local Treatment in High Risk Localized Prostate Cancer

    Prague, Czech Republic (UroToday.com) Dr. Paul Nguyen took the stance for radiation therapy in this much-anticipated debate regarding appropriate local treatment in men with high risk localized prostate cancer.
    Published January 21, 2019
  • First Human Application of Novel PET Tracer for Prostate Cancer

    New tracer holds promise of monitoring targeted treatment of various cancers

    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
    Published August 10, 2017
  • From the Desk of the Associate Editor: The Diverse Use of PET/CT Diagnostic Imaging for Prostate Cancer

    This comprehensive review summarizes important clinical concepts in the rapidly advancing field of positron emission tomography/computed tomography (PET/CT) for prostate cancer. The authors reviewed 18F-NaF-, choline-, fluciclovine- and prostate-specific membrane antigen (PSMA)-based modalities in primary disease staging and assessment of biochemical recurrence. The most thoroughly studied modality to date is choline PET/CT.
    Published October 18, 2018
  • Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.

    The prostate-specific membrane antigen (PSMA) was shown to be overexpressed on the neovasculature of several malignancies. Here, the role of Ga-HBED-CC-PSMA PET/CT for the detection of PSMA expression in patients with metastasized differentiated thyroid cancer (DTC) was evaluated.

    Published November 24, 2016
  • Imaging Response During Therapy with Radium-223 For Castration-Resistant Prostate Cancer With Bone Metastases—Analysis Of An International Multicenter Database

    BACKGROUND: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment.

    METHODS: We retrospectively evaluated the computed tomography (CT) and bone scintigraphy response of metastatic castration-resistant prostate cancer (CRPC) patients treated with radium-223, in eight centers in three countries.
    Published June 1, 2017
  • MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

    Background: Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.
    Published March 19, 2018
  • Novel Nuclear Medicine Test Can Identify Kidney Transplant Infection

    Truckee, CA (UroToday.com)  German scientists have developed a novel nuclear medicine test that can determine whether a kidney transplant patient has developed infection in the transplanted tissue. The study, which utilizes positron emission tomography/magnetic resonance imaging (PET/MRI), is presented in the November issue of The Journal of Nuclear Medicine.  
    Published November 10, 2017
  • Novel PET Imaging Agent Targets Copper in Tumors to Detect Prostate Cancer Recurrence Early

    Truckee, CA (UroToday.com) An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level). 
    Published March 7, 2018
  • Optimization of labeling PSMAHBED with 68Ga and its quality control systems.

    Radiolabeling of the prostate-specific membrane antigen (PSMA) inhibitor, Glu-NH-CO-NH-Lys (Ahx), using the (68)Ga chelator HBED-CC (PSMAHBED) allows imaging of lesions of prostate cancer due to the high expression of PSMA in prostate carcinoma cells as well as bone metastases and lymph nodes related to the disease.

    Published January 18, 2017
  • Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging: Beyond the Abstract

    68Ga-PSMA-PET imaging seems to be becoming the new state of the art imaging modality in prostate cancer. Especially in a salvage setting it is often doubtful where sites of recurrence may be. Now this research intends to somewhat clear that question by uncovering typical sites of recurrence after prostatectomy. 
    Published July 13, 2017
  • PET imaging of (64)Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs.

    Single chain (scFv) antibodies are ideal targeting ligands due to their modular structure, high antigen specificity and affinity. These monovalent ligands display rapid tumor targeting but have limitations due to their fast urinary clearance.

    Published February 2, 2017
  • PET Scan Identifies Which Prostate Cancer Patients Can Benefit from Salvage Radiation Treatment

    TRUCKEE, CA (UroToday.com) For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after radical prostatectomy, early treatment makes a difference. In a study featured in the December issue of The Journal of Nuclear Medicine, Australian researchers demonstrate that PET scans can identify which of these prostate cancer patients would benefit from salvage radiation treatment (SRT).
    Published December 5, 2017
  • Practice-Changing Applications of Radiology and Nuclear Medicine in Genitourinary Malignancies

    Published in Everyday Urology - Oncology Insights: Volume 3, Issue 4
    Experts at Harvard Business School first coined the term disruptive innovation to describe how small, poorly resourced companies could successfully challenge larger ones.1 More than two decades later, this concept is central in medicine, where innovations in everything from proteomics and wearables to electronic health records and health economics are upending our status quo.2,41
    Published February 27, 2019
  • Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer.

    Sarcosine is a known substrate of proton-coupled amino acid transporters (PATs), which are overexpressed in selected tissues and solid tumors. Sarcosine, an N-methyl derivative of the amino acid glycine and a metabolic product of choline, plays an important role for prostate cancer aggressiveness and progression. 
    Published August 10, 2017
  • PSMA PET/CT Clearly Differentiates Prostate Cancer from Benign Tissue

    Truckee, CA (UroToday.com) Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine.
    Published February 6, 2018
  • Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT

    The purpose of this study was to evaluate the outcome after Radium-223-dichloride ((223)RaCl₂) treatment of patients with skeletal metastases of castration resistant prostate cancer using whole-body (18)F-Fluoride PET/CT.  
    Published April 7, 2017
  • Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT: Beyond the Abstract

    This article [1] is a comprehensive analysis of 10 prostate cancer patients who received Ra-223-treatments. These patients were imaged with multiple quantitative PET methods according to our own algorithm [2], including fluoro-18-choline-PET and sodium fluoride-18 PET. These patients were additionally treated with multidisciplinary methods, including other radiation therapies. We recently reported an overall survival of 8.4 years in 46 patients of high-risk T3-4NXM1 primarily metastatic prostate cancer [2].
    Published April 7, 2017
  • Randomized Prospective Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT] - Beyond the Abstract

    Curative treatments for localized PCa include radical prostatectomy or radiotherapy2. After the failure of local therapy, recurrence is detected by rising serum PSA levels. Biochemical recurrence (BCR) occurs in 20 to 80% of patients within 10 years after radical prostatectomy. Locally recurrent disease after radical prostatectomy may be cured by salvage radiation therapy (SRT).
    Published January 31, 2019
  • Rare Sites of Metastases in Prostate Cancer Detected on Ga-68 PSMA PET/CT Scan-A Case Series.

    Ga-68 labeled prostate-specific membrane antigen (PSMA) whole body PET/CT scan is a novel upcoming modality for the evaluation of prostate cancer. We present three cases of prostate cancer showing rare sites of metastases like brain, penis, and liver detected on Ga-68 PSMA PET/CT scan thus emphasizing its role in lesion detection and staging.

    Published March 10, 2017
  • SNMMI 2016: 11C-acetate PET/CT accurately predicts prostate-cancer specific survival in patients with biochemical relapse after prostatectomy

    San Diego, CA. USA (UroToday.com) – 11Choline-acetate (11C-acetate) has been used as an investigational PET radiopharmaceutical to image patients with prostate cancer based on elevated transports in prostate cancers after prostatectomy to detect recurrence and metastasis upon biochemical relapse.  Its utility for predicting outcomes in this group of patients has not been reported.  Naresh Kumar Regula, from the Uppsala University, Sweden presented new data at the 2016 Society of Nuclear Medicine and Molecular Imaging annual meeting.  The question of whether parameters measured by 11C-acetate PET correlate with clinical outcomes including survival.
    Published July 11, 2016
  • SNMMI 2016: Application of 18F-labeled PSMA-imaging using [18F]DCFPyL at very low PSA-values may allow curative treatment in recurrent prostate cancer.

     

    San Diego, CA. USA (UroToday.com) – Newer and more sensitive radioligands are available for imaging PSMA to detect prostate cancer recurrence and metastasis upon biochemical relapse.  Ga-68 labeled PSMA-HBED-CC (or Ga-PMSA-11) is a Ga-68 labeled monoclonal antibody against PMSA while F-18 DCFPyL is a small molecule with high affinity to PSMA at nanomolar range. Both are investigational radiopharmaceuticals with high PSMA-affinity that hold great potential for clinical use.  They may be able to provide early diagnostic information for possible curative treatment of recurrent prostate cancers that are limited to the prostate fossa and regional lymph nodes.

    Published July 11, 2016
  • SNMMI 2016: Fluciclovine F18 (FACBC): An Amino Acid Tracer for the Staging of Recurrence Prostate Cancer

    San Diego, CA. USA (UroToday.com) – Coming off the recent FDA approval of Flucicovine F18 (FACBC), trade name Axumin®, it was with obvious excitement the CEO of Blue Earth Diagnostics discussed the research which lead to the recent news. Flucicovine is a synthetic amino acid based PET agent, which has been approved in men with suspected prostate cancer recurrence based on elevated PSA. 
    Published July 11, 2016
  • SNMMI 2016: Fluciclovine F18 PET-CT scanning in patients with high-risk primary prostate carcinoma

    San Diego, CA. USA (UroToday.com) – F-18 fluciclovine (FACBC) has been used as an investigational PET radiopharmaceutical to image patients with prostate cancer based on elevated amino acid transports in prostate cancers.  Its utility for disease staging has not been established for patients with high-risk primary prostate cancer. 
    Published July 11, 2016
  • SNMMI 2016: PET/CT Imaging of Prostate Cancer Proves Accurate Biopsy Guide



    Study shows imaging of prostate-specific membrane antigen leads to highly accurate tumor detection and delineation


    San Diego, Calif. (June 15, 2016) – Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of defense, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and pre-operative planning to root out the full extent of disease, researchers revealed at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

    Published July 11, 2016
  • Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.

    We report our initial clinical experience with β -emitting (177)Lu-PSMA-I&T ((177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic treatment of metastatic castration resistant prostate cancer.
    Published August 31, 2017
  • The Use of PET/CT in Prostate Cancer - Full Text Article

    Background: Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy for cancer detection in various clinical settings. In this review, we aim to illustrate the diverse use of PET/CT with different tracers for the detection of prostate cancer.
    Published October 18, 2018
  • Theranostics: Paintball Targeting of Cancer Cells Combined with Precision Therapy

    Truckee, CA (UroToday.com)  The Journal of Nuclear Medicine’s September 2017 supplement shines a spotlight on theranostics and its increasingly important role in the delivery of precision medicine. Theranostics refers to the combination of a predictive biomarker, identified through diagnostic imaging using radiolabeled ligands (which lock onto the specific cancer cell receptor/biomarker), with precise therapy targeted on the now-marked cancer cells. The cancer cells are destroyed, while healthy cells are unharmed—minimizing side effects and improving quality of life for patients.
    Published September 15, 2017
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe